US Pre-Market SEC Filings Roundup — September 14, 2026

14-09-2026

Zhihu Inc. filed a Form 6-K with the SEC for September 2026, attaching its 2026 Interim Report and several Next Day Disclosure Returns related to share repurchases or other corporate actions. The filing provides updated financial and operational information for the first half of 2026. However, the interim report details are not included in this structured filing, so quantitative performance metrics are not available for analysis.

• · The filing includes Next Day Disclosure Returns dated September 9, 10, and 11, 2026, suggesting recent share repurchase activity.
• · The registrant is a foreign private issuer filing under Form 20-F annual reporting requirements.

14-09-2026

Clearmind Medicine Inc. announced the enrollment of the first two patients with Alcohol Use Disorder (AUD) in its Phase I clinical trial of CMND-100, a proprietary psychedelic-based treatment candidate. The patients were enrolled at Hadassah Medical Center in Jerusalem, Israel, marking the first administration of CMND-100 to AUD patients after prior evaluation in healthy participants. The trial is designed to assess safety, tolerability, pharmacokinetics, and preliminary efficacy, with the CEO highlighting positive enrollment momentum and progress toward key milestones.

• · CMND-100 is a non-hallucinogenic psychedelic-derived neuroplastogen.
• · The trial is ongoing and previously evaluated CMND-100 at multiple doses in healthy participants.
• · Clearmind's intellectual portfolio includes 19 patent families and 32 granted patents.
• · The company is listed on Nasdaq under the symbol 'CMND'.

14-09-2026

Radiopharm Theranostics Ltd (RDPTF) filed a shelf registration statement on Form F-3 with the SEC, registering 1,345,728 American Depositary Shares (ADSs) representing 403,718,400 ordinary shares. The filing enables the company to offer and sell these securities from time to time in one or more offerings, incorporating by reference several prior reports filed with the SEC and ASX. This is a routine capital markets action with no financial results or performance data disclosed.

14-09-2026

Li Auto Inc. filed a Form 6-K with the SEC for September 2026, including next day disclosure returns dated September 8, 10, and 11, 2026. The filing was signed by Director and CFO Tie Li. No specific financial results or material changes were disclosed.

• · Form 6-K filed with the SEC on September 14, 2026
• · Exhibits include Next Day Disclosure Returns dated September 8, 10, and 11, 2026 (details not provided in the filing text)

14-09-2026

Toyota Motor Corporation filed an Amendment No. 1 to its Schedule 13G with the SEC on September 14, 2026, reporting that it beneficially owns 0 Class A ordinary shares of Grab Holdings Ltd as of September 9, 2026. This represents a 0.0% ownership stake, calculated based on 3,969,290,878 Class A ordinary shares outstanding. The filing indicates Toyota has fully exited its previously reported position in Grab.

• · Toyota's beneficial ownership is 0 shares, representing 0.0% of Grab's Class A ordinary shares.
• · The filing is an amendment to the original Schedule 13G filed on December 9, 2021.
• · Toyota certifies the securities were not acquired or held for changing or influencing control of Grab.

14-09-2026

Dr. Phillip Frost and Frost Gamma Investments Trust disclosed a 9.82% beneficial ownership stake in Safe Pro Group Inc. (SPAI) as of September 9, 2026, holding 2,000,000 shares (including 1,000,000 shares of common stock and an option to purchase 1,000,000 shares). The filing is a Schedule 13G, indicating passive investment intent, and the stake is valued based on 20,362,862 shares outstanding as of August 14, 2026.

• · The filing is a Schedule 13G under Rule 13d-1(c), indicating passive investment intent, not an activist position.
• · The 2,000,000 share stake consists of 1,000,000 shares of common stock and an option to purchase 1,000,000 shares, both held by Frost Gamma Investments Trust.
• · Dr. Frost disclaims beneficial ownership of the securities held by FGIT except for any pecuniary interest.
• · The filing date is September 14, 2026, with the event date of September 9, 2026.

14-09-2026

Prudential PLC repurchased 3,504,263 of its own shares on the London Stock Exchange (XLON) over the week of September 7–11, 2026, at volume-weighted average prices ranging from £9.8438 to £10.2471 per share. The buyback activity was consistent each day, with the highest volume on September 9 (737,500 shares) and the lowest on September 7 (640,153 shares). The share price declined over the week, with the lowest price paid falling from £10.1650 on September 7 to £9.7760 on September 11.

• · The lowest price paid per share during the week was £9.7760 on September 11, and the highest was £10.3000 on September 7.
• · The volume-weighted average price declined each day from £10.2471 on September 7 to £9.8438 on September 11.

14-09-2026

WhiteFiber, Inc. filed an 8-K on September 14, 2026, furnishing an investor presentation under Regulation FD. The presentation highlights the company as an AI infrastructure provider with a $2.5 billion contracted backlog, $865 million in annualized revenue from signed contracts, and a recent $7.0 billion in cloud total contract value (TCV) announced since May 2026. However, the filing contains no historical financial results or period-over-period comparisons, so performance trends cannot be assessed.

• · The investor presentation includes forward-looking projections and non-GAAP measures (EBITDA, Adjusted EBITDA) but no audited or historical financial data.
• · The company is an emerging growth company and has elected not to use the extended transition period for complying with new accounting standards.
• · The filing is furnished under Item 7.01 and is not deemed filed for Section 18 liability purposes.

14-09-2026

Electra Therapeutics, Inc. filed an S-1/A registration statement for its initial public offering on September 14, 2026. The company expects net proceeds of approximately $296.6 million from the offering, based on an assumed midpoint IPO price of $15.00 per share. The filing details material risks, including potential internal control deficiencies, inadequate insurance coverage, and forward-looking statements about its product candidates ipsoprubart and ELA822.

• · Electra Therapeutics has never declared or paid any cash dividends and does not intend to pay dividends for the foreseeable future.
• · The filing includes a special note regarding forward-looking statements, highlighting substantial risks and uncertainties.
• · The company qualifies as an emerging growth company under the JOBS Act and will not be required to include an attestation report on internal control over financial reporting.
• · The company does not have a formal risk management program for identifying and addressing business risks.
• · Insurance policies may be inadequate and may not cover all potential liabilities.

14-09-2026

On September 12, 2026, Oracle disclosed that Executive Chair and CTO Larry Ellison cancelled his 10b5-1 plan to sell Oracle stock. No shares were sold under the plan before its termination. The cancellation removes a potential overhang on the stock and signals insider confidence, but the filing provides no financial results or other operational updates.

• · The 10b5-1 plan was cancelled on September 12, 2026.
• · No Oracle stock was sold under the plan prior to termination.
• · The cancellation was announced via a press release attached as Exhibit 99.1.

14-09-2026

Apogee Therapeutics, Inc. filed a Form 15 with the SEC on September 14, 2026, to terminate its registration under Section 12(g) of the Securities Exchange Act of 1934. The company reported only one holder of record as of the certification date, indicating it is no longer publicly traded and has suspended its duty to file reports with the SEC. The filing is signed by Scott T. Reents, President, and lists the company's address as c/o AbbVie, Inc., suggesting a corporate integration.

• · The company's principal executive offices are located at c/o AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois.
• · The phone number for the principal executive offices is (847) 932-7900.
• · The common stock has a par value of $0.00001 per share.
• · The filing relies on Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i) to terminate registration and suspend filing duties.
• · The commission file number is 001-41740.

14-09-2026

Artificial Intelligence Technology Solutions Inc. (AITX) filed a Form 8-K on September 14, 2026, announcing that its subsidiary RAD (Robotic Assistance Devices) is going live on the Immix platform with its ROSA and RIO products. The announcement was made via a press release attached as Exhibit 99.1. No financial figures or operational metrics were disclosed in the filing.

• · The press release is dated September 14, 2026, and is attached as Exhibit 99.1.
• · The filing is furnished under Item 8.01 and is not deemed 'filed' for Section 18 purposes.
• · The company's principal executive offices are located at 10800 Galaxie Avenue, Ferndale, Michigan.

14-09-2026

Nomura Holdings Inc. reported its monthly share repurchase activity under a board authorization from January 30, 2026, covering the period from February 17, 2026 to September 30, 2026. During the reporting month (likely August 2026), the company did not repurchase any shares. However, cumulatively as of the end of that month, Nomura had repurchased 46,861,200 shares for JPY 59,999,879,300, reaching 46.9% of the authorized share count but 100.0% of the authorized repurchase amount.

• · The repurchase authorization was resolved by the Board on January 30, 2026, with a period from February 17, 2026 to September 30, 2026, excluding the ten business days following the announcement of each quarterly financial results.
• · No shares were repurchased during the reporting month, implying the company may have hit the monetary cap or paused activity.
• · The company exhausted 100% of the authorized repurchase amount (JPY 60 billion) but only 46.9% of the authorized share count (100 million shares), indicating a higher average repurchase price than anticipated.

14-09-2026

KE Holdings Inc. filed a Form 6-K with the SEC for September 2026, attaching three Next Day Disclosure Returns dated September 7, 9, and 11, 2026. The filing is a routine foreign issuer report and does not contain any financial results, material transactions, or operational updates.

• · The filing includes three Next Day Disclosure Returns dated September 7, 9, and 11, 2026, but their content is not disclosed in the 6-K.

14-09-2026

Woodside Energy Group Ltd filed a Form 6-K with the SEC on September 14, 2026, disclosing an ASX announcement titled 'Resignation of Director.' The filing confirms the resignation of a director from the board, effective as of the announcement date. No financial figures or operational metrics were provided in this disclosure.

• · The resignation was announced via ASX on September 14, 2026.
• · The filing was made under Form 6-K for the month of September 2026.
• · The resigning director's name was not disclosed in the filing.

14-09-2026

Biophytis S.A. completed a €5.3 million capital increase to fund its Phase 2 obesity trial, as disclosed in a Form 6-K filed with the SEC on September 11, 2026. The filing includes only this single positive corporate update with no comparative period data, financial results, or other metrics to provide a balanced view of performance.

• · The capital increase of €5.3 million is specifically designated to fund the Phase 2 obesity trial.
• · The filing is a Form 6-K under the Securities Exchange Act of 1934.
• · The report was signed by Stanislas Veillet on September 11, 2026.

14-09-2026

Nanobiotix S.A. filed a Form 6-K with the SEC on September 14, 2026, attaching a press release issued the same day. The filing is a routine foreign private issuer report, and no financial results or material business updates are disclosed in the filing itself.

• · The filing is a Form 6-K for the month of September 2026.
• · The press release is attached as Exhibit 99.1 and incorporated by reference.
• · The company's principal executive office is located at 60 Rue de Wattignies, 75012 Paris, France.

14-09-2026

Cellectis S.A. filed a Form 6-K with the SEC on September 14, 2026, attaching a press release of the same date. The filing is a routine foreign private issuer report, with no specific financial results or material corporate events disclosed in the cover filing itself.

• · The filing is a Form 6-K for the month of September 2026.
• · The press release referenced as Exhibit 99.1 is dated September 14, 2026.
• · The registrant's principal executive office is at 8, rue de la Croix Jarry, 75013 Paris, France.

14-09-2026

Caledonia Mining Corporation Plc filed a Form 6-K with the SEC on September 14, 2026, attaching a press release of the same date. The filing is a routine foreign issuer report and does not contain any financial results, material events, or performance data.

• · The filing is a Form 6-K for the month of September 2026.
• · The press release is dated September 14, 2026, but its content is not included in the filing excerpt.

14-09-2026

Eaglesky Acquisition Corp filed an S-1/A registration statement with the SEC for an IPO of 10,000,000 units at $10.00 per unit, targeting gross proceeds of $100 million. The company is a Cayman Islands blank check company focused on U.S. targets, with a 24-month deadline to complete a business combination. However, the company faces significant risks due to ties to China among its officers and directors, potential CFIUS scrutiny, and the possibility of PRC regulatory intervention, which could limit its target pool or hinder the offering.

• · The company will not consider or undertake an initial business combination with any entity with its principal business operations in China (including Hong Kong and Macau).
• · The company will not consider or undertake an initial business combination with any company whose financial statements are audited by an accounting firm that the PCAOB has been unable to inspect for two consecutive years.
• · The company is not required to obtain approvals from the CSRC, CAC, or any other PRC government agency for this offering, but PRC agencies could reach a different conclusion.
• · The company may be considered a 'foreign person' under CFIUS rules, potentially limiting its ability to complete a business combination with a U.S. target.
• · The company has not made any transfers, dividends, or distributions to any person or entity as of the prospectus date.
• · The company does not intend to pay cash dividends in the foreseeable future.
• · The offering is on a firm commitment basis.
• · The company is an 'emerging growth company' and a 'smaller reporting company' under federal securities laws.

14-09-2026

Thomson Reuters Corporation filed a Form 6-K with the SEC for September 2026, primarily to attach an Underwriting Agreement dated September 10, 2026, related to a debt securities offering. The filing also incorporates the exhibit into its existing shelf registration statements on Form F-10 and Form F-3. No financial results or operational metrics were disclosed in this filing.

• · Underwriting Agreement dated September 10, 2026, filed as Exhibit 99.1
• · Exhibit incorporated by reference into registration statements on Form F-10 and Form F-3 (File Nos. 333-285907, 333-285927, 333-285927-01, 333-285927-02, 333-285927-03)
• · Filing made for the month of September 2026
• · Registrant address: 19 Duncan Street, Toronto, Ontario M5H 3H1, Canada

14-09-2026

United Natural Foods Inc (UNFI) reported a financial turnaround in fiscal year 2026, posting net income of $84 million compared to a net loss of $118 million in FY2025. The improvement was driven by a $31 million swing to operating income of $211 million and a 27% increase in Adjusted EBITDA to $701 million. However, total net sales declined 2.0% to $31,152 million, with weakness in the Conventional segment (-11.5%) and Retail segment (-7.9%) partially offset by 7.0% growth in Natural segment sales.

• · Net cash provided by operating activities was $540 million in FY2026, up from $470 million in FY2025.
• · Cash and cash equivalents declined to $37 million at August 1, 2026 from $44 million at August 2, 2025.
• · The company has $1,237 million variable-rate debt maturing largely in 2031, with a weighted-average interest rate of 5.8%.
• · Total liabilities decreased 9.2% from $6,041 million to $5,487 million, while total stockholders' equity increased 4.4% from $1,554 million to $1,622 million.
• · Goodwill remained unchanged at $19 million, while intangible assets net decreased 11.7% from $576 million to $509 million.
• · The company's LIFO charge reversed to $19 million in FY2026 from a benefit of ($2) million in FY2025.
• · Interest expense, net, declined 13.7% from $146 million to $126 million.

14-09-2026

Autolus Therapeutics plc filed a Form S-3 shelf registration on September 11, 2026, covering the resale of up to 3,500,000 ADSs by a selling securityholder upon exercise of a warrant with an exercise price of $1.9314 per ADS. The company will not receive any proceeds from the ADS sales but would receive the warrant exercise price if exercised for cash. The filing highlights Autolus as a commercial-stage biopharma with its approved CAR-T therapy AUCATZYL (obe-cel) for r/r B-ALL, with FDA approval in November 2024 and a US commercial launch in January 2025. However, the company notes that EU launch is on hold with no anticipated 2026 sales in the EU, and the Phase 2 data for the autoimmune indication is not expected until 2028.

• · US FDA approval of AUCATZYL obtained in November 2024.
• · US commercial launch of AUCATZYL occurred in January 2025.
• · UK conditional marketing authorization granted in April 2025; NICE recommendation in November 2025; UK launch in January 2026.
• · EU marketing authorization granted in July 2025, but EU launch is on hold with no anticipated 2026 sales.
• · Phase 2 lupus nephritis data expected in 2028.
• · First preliminary results for progressive multiple sclerosis trial expected in Q1 2027.
• · Company continues to qualify as a foreign private issuer but voluntarily files on US domestic issuer forms.

14-09-2026

Skyworks Solutions, Inc. announced an extension of the expiration date for its exchange offers for Qorvo's senior notes due 2029 and 2031, now set for September 18, 2026. As of September 11, 2026, 90.85% of the 2029 notes ($772.3M of $850M outstanding) and 93.43% of the 2031 notes ($654.0M of $700M outstanding) had been validly tendered, indicating strong bondholder participation. The exchange offers are conditioned on the closing of the merger between Skyworks and Qorvo, which Skyworks hopes to close within the calendar year, though no assurances are given.

• · The exchange offers are conditioned on the closing of the merger, but the merger is not conditioned on the exchange offers.
• · Settlement is expected no earlier than the second business day after the merger closing date.
• · Holders who already tendered do not need to re-tender; their tenders remain effective.
• · The dealer manager for the exchange offers is Goldman Sachs & Co. LLC.

14-09-2026

Polaryx Therapeutics, Inc. held its Annual Meeting of Stockholders on September 10, 2026, and reported voting results. The ratification of Grant Thornton LLP as the independent registered public accounting firm for fiscal year 2026 was approved with 30,510,106 votes in favor. Directors were elected to serve until the 2029 annual meeting, though specific vote counts for director elections were not disclosed in the filing.

• · Annual Meeting held on September 10, 2026
• · Directors elected to serve until the 2029 annual meeting
• · Ratification of Grant Thornton LLP as independent auditor for fiscal year ending December 31, 2026
• · Company is an emerging growth company and has elected not to use the extended transition period for complying with new financial accounting standards
• · Common stock trades on Nasdaq under ticker symbol PLYX

14-09-2026

MOBIX LABS, INC is seeking stockholder approval for a reverse stock split (ratio between 1:2 and 1:20) as a precautionary measure to maintain its Nasdaq listing. The company previously effected a reverse split on April 6, 2026, and under Nasdaq rules, it is not entitled to a compliance period for a new bid price deficiency, meaning it could face immediate delisting if the bid price falls below $1.00. While the stock closed at $1.12 as of September 10, 2026, the company acknowledges that its prior reverse split was followed by a decline in stock price and market value, and there is no assurance the proposed split will achieve sustained price improvement.

• · The reverse split ratio range is 1:2 to 1:20, with the exact ratio and timing determined by the Board within 12 months of stockholder approval.
• · The Board may abandon the reverse split entirely even if approved.
• · All outstanding shares of Class B Common Stock were converted into Class A Common Stock prior to the Record Date; no Class B shares remain outstanding.
• · Fractional shares resulting from the reverse split will be rounded up to the nearest whole share.
• · The reverse split would not change the par value or the number of authorized shares of capital stock.
• · The company previously effected a reverse stock split on April 6, 2026, and following that split, the stock price and market value declined.
• · If delisted from Nasdaq, the stock could become a 'penny stock,' subject to additional state regulations and reduced trading liquidity.
• · Delisting could impair the company's ability to raise capital and provide stock-based incentives.

14-09-2026

Petrobras received R$ 2,567.5 million (approx. USD 500M) in new installments under Brazil's Diesel Economic Subvention Program, covering diesel sales from June 1-30, 2026. The cumulative total received by Petrobras to date under diesel, gasoline, and LPG subsidy programs amounts to approximately R$ 9.5 billion. This is a routine operational update regarding government subsidy payments, not a material change in the company's financial outlook.

• · The first installment of R$ 643.8 million covers diesel sales from June 1 to 15 under Provisional Measure No. 1,358.
• · The second installment of R$ 1,923.7 million covers diesel sales from June 16 to 30 under Provisional Measure No. 1,363.
• · The cumulative total of R$ 9.5 billion includes payments under diesel, gasoline, and LPG subsidy programs.

14-09-2026

BioLargo, Inc. filed an 8-K/A to add the transcript of an investor webcast held on September 10, 2026, at 1:00 PM Pacific Time. The filing includes a slide deck (Exhibit 99.1) and the webcast transcript (Exhibit 99.2) as Regulation FD disclosures. No financial results or material operational changes were reported in this amendment.

• · The filing is an amendment (No. 1) to a previous 8-K, adding the webcast transcript as Exhibit 99.2.
• · The webcast occurred on September 10, 2026, at 1:00 PM Pacific Time.
• · The information is furnished under Item 7.01 and is not deemed filed for SEC liability purposes.

14-09-2026

abrdn Global Infrastructure Income Fund (ASGI) filed an 8-K on September 14, 2026, announcing that its Board of Trustees approved the issuance of transferable rights to common shareholders as of a record date, allowing them to subscribe for additional common shares. The press release was issued on September 11, 2026, and is included as Exhibit 99.1. No financial figures or performance metrics were disclosed in this filing.

• · Rights issuance approved by the Board of Trustees on September 11, 2026.
• · Rights will be issued to holders of Common Shares as of the record date.
• · Rights entitle holders to subscribe for additional Common Shares.
• · Press release dated September 11, 2026, included as Exhibit 99.1.
• · Fund is registered under the Investment Company Act (File No. 811-23490).
• · Common shares trade on the New York Stock Exchange under ticker ASGI.

14-09-2026

ZK International Group Co., Ltd. announced the resignations of Director and Chairman Jiancong Huang and CFO Xiaofen Jin, effective September 10, 2026, with no disagreement cited. Ruihong Ma was appointed as Chairman and CFO to fill the vacancies, while continuing as CEO. The leadership reshuffle introduces potential governance and succession risk.

• · Resignations and appointments are effective September 10, 2026.
• · Mr. Ma was elected by the remaining Board members to fill both vacancies.
• · Mr. Ma now holds Chairman, CFO, and CEO roles concurrently.
• · Both resigning executives stated no disagreement with Company operations, policies, or practices.

14-09-2026

Leader's Advantage Acquisition Corp., a blank check company, filed Amendment No. 2 to its S-1 registration statement for an initial public offering of 15,000,000 units at $10.00 per unit, aiming to raise $150,000,000. The company has not yet selected a business combination target and has not initiated any substantive discussions with any target. The offering includes a 45-day over-allotment option for underwriters to purchase up to an additional 2,250,000 units, and the sponsor has committed to a private placement of 1,750,000 warrants for $3,500,000.

• · The company is a blank check company incorporated in the Cayman Islands.
• · No business combination target has been selected, and no substantive discussions have been initiated.
• · The underwriters have a 45-day option to purchase up to an additional 2,250,000 units to cover over-allotments.
• · Public shareholders have redemption rights upon completion of an initial business combination, but shareholders holding more than 15% of shares sold in the offering may be restricted from redeeming more than 15% without prior consent.
• · The sponsor purchased 4,312,500 Class B ordinary shares for $25,000, resulting in immediate and substantial dilution for public shareholders.
• · The company may enter into non-redemption or forward-purchase agreements, but none have been entered into or are currently contemplated.
• · The offering is subject to completion and the registration statement is not yet effective.

14-09-2026

Bullseye Investment Management, LLC filed its quarterly 13F-HR for the period ended March 31, 2026, reporting approximately $185.8 million in total disclosed equity holdings across 320 positions. The portfolio is heavily concentrated in First Trust exchange-traded funds (especially FT Vest series) and Innovator ETFs, alongside major individual holdings in Apple, Amazon, Alphabet, Eli Lilly, and Broadcom. The filing provides a snapshot of the firm's long equity positions as of quarter-end, with no prior-period comparison available in this filing.

• · Top individual equity holdings by share count include Apple (249,476 shares), Amazon (250,694 shares), Alphabet Class C (415,660 shares), Eli Lilly (237,300 shares), and Broadcom (273,792 shares).
• · The largest ETF positions are in First Trust FT Vest U.S. Equity Buffer series (e.g., 543,089 shares of FT Vest U.S. Equity Buffer - April, 274,221 shares of FT Vest Laddered series, and 203,766 shares of FT Vest Technology).
• · Innovator ETFs are heavily represented, with top positions including US Equity Power Buffer (113,654 shares), US Equity 10 Buffer (237,330 shares), and US Equity Accelerated (264,204 shares).
• · Direxion leveraged single-stock ETFs are present: 58,632 shares of MSFT Bull 2X, 43,592 shares of META Bull 2X, and 6,648 shares of AVGO Bull 2X.
• · Smaller speculative holdings include D-Wave Quantum (17 shares), Clover Health Investments (4,350 shares), and Hycroft Mining (1,000 shares).
• · The filing reports 320 positions with total value of $185,792,036, but no prior-period comparison is available to assess portfolio turnover or changes.

14-09-2026

Faraday Future Intelligent Electric Inc. filed a shelf registration statement on Form S-3 with the SEC on September 11, 2026, allowing selling stockholders to offer and sell shares of Class A Common Stock from time to time, and also covering shares issuable upon conversion of any Notes. The company will not receive any proceeds from sales by selling stockholders. The filing highlights significant risk factors, including the company's ability to raise sufficient funds to continue operations, ongoing SEC and DOJ investigations, and material weaknesses in internal control over financial reporting.

• · The company's Class A Common Stock trades on The Nasdaq Capital Market.
• · The company has operations in the United Arab Emirates, including an entity for FF 91 series assembly and sales support and a facility in Ras Al Khaimah intended to support future FX Super One production.
• · The company was founded in 2014 and is headquartered in the greater Los Angeles, California area.
• · The company manufactures vehicles at the FF aiFactory California production facility in Hanford, California.
• · The filing incorporates by reference the company's Annual Report on Form 10-K for the year ended December 31, 2025.
• · Risk factors include ongoing SEC and DOJ investigations, material weaknesses in internal control over financial reporting, and the company's ability to raise sufficient funds.

14-09-2026

NorthStrive Acquisition Corp I. filed an 8-K on September 14, 2026, announcing the adoption of corporate governance policies and committee charters effective September 9, 2026, following its August 2026 IPO. The policies include a Code of Conduct and Ethics, Insider Trading Compliance Policy, and a Clawback Policy, along with charters for the Compensation, Nominating, and Audit Committees. No financial results or business combination updates were disclosed.

• · The policies were adopted on September 10, 2026, effective as of September 9, 2026.
• · The Clawback Policy complies with Nasdaq listing rules and Section 10D of the Exchange Act.
• · The related-party transaction threshold is set at $120,000 per calendar year.
• · The Audit Committee is responsible for investigating and enforcing the Code of Conduct and Ethics.

14-09-2026

Einride AB, a Swedish provider of electric and self-driving trucking solutions, filed an F-1 registration statement with the SEC on September 14, 2026, for a potential initial public offering. The filing includes financial data for the six months ended June 30, 2026, and 2025, as well as full-year 2025 and 2024, showing revenue growth and cost structure details. However, the filing also reveals significant operating losses and negative retained earnings, indicating the company is not yet profitable.

• · The filing covers periods: H1 2026, H1 2025, FY 2025, FY 2024, and FY 2023.
• · Revenue segments include Transport Services, Rental Income, and geographic breakdowns (Sweden, United States, Germany, All Other Countries).
• · Cost components include Contract Driver Costs, Depreciation and Amortization, Transport Costs, Staff Costs, Advertising Costs, Legal and Court Costs, Insurance, IT and Software Expenses, Hardware Development Costs, Government Grants, Exchange Rate Losses, and Other Finance Costs.
• · The company has negative retained earnings as of June 30, 2026, indicating accumulated losses.
• · The company has two largest customers contributing to revenue, with specific data for H1 2026 and FY 2024.

14-09-2026

BioVie Inc. entered into a Sales Agreement with A.G.P./Alliance Global Partners on September 11, 2026, to sell up to $6,464,341 of its Class A common stock in at-the-market offerings. The company will pay a 3.0% commission on gross proceeds and intends to use the funds for general corporate purposes. The agreement provides flexibility but does not obligate the company to sell any shares.

• · The Registration Statement (File No. 333-296924) was filed on June 18, 2026 and declared effective on June 29, 2026.
• · The prospectus supplement was filed with the SEC on September 11, 2026.
• · The Sales Agreement may be terminated by either party, and the company may suspend offers at any time.
• · The offering will terminate upon the earlier of: (a) sale of all Placement Shares, (b) expiration of the Registration Statement on the third anniversary of its effective date, or (c) termination of the Agreement.

14-09-2026

National Steel Company (CSN) received a non-compliance notice from the NYSE on August 13, 2026, because its ADS average closing price fell below $1.00 over 30 consecutive trading days. The company has a six-month cure period and is evaluating options to regain compliance. Since receiving the notice, CSN's ADSs have appreciated and are currently trading above the $1.00 threshold, but the risk of delisting remains if compliance is not maintained.

• · The non-compliance notice was received on August 13, 2026.
• · The cure period is six months from receipt of the notice.
• · The notice does not result in immediate delisting.
• · CSN has notified the NYSE of its intention to cure.
• · Since receipt of the notice, ADSs have appreciated and are currently trading above the $1.00 minimum threshold.

14-09-2026

InPoint Commercial Real Estate Income, Inc. announced a reduction in its monthly distribution from an undisclosed prior level to $0.026 per share, effective for stockholders of record as of September 30, 2026, citing the need to better align distributions with current portfolio earnings and cash flows. While the company has resumed originating new loans and is encouraged by stabilizing commercial real estate lending markets, it continues to face challenges from legacy investments and a lack of liquidity. Management is accelerating efforts to evaluate strategic alternatives, including engaging an investment bank, to enhance stockholder value and improve liquidity.

• · The distribution reduction applies to all share classes, but Class D, S, and T holders will receive net amounts after stockholder servicing fees, resulting in a lower annualized rate than Class I and P.
• · The company's share repurchase plan remains suspended, and there is no trading market for its common stock.
• · The board will continue to declare distributions quarterly, and future payments are not guaranteed.
• · The company filed its most recent Annual Report on Form 10-K on March 13, 2026.

14-09-2026

Hydro One Ltd furnished a Form 6-K to the SEC for the month of September 2026, attaching a news release dated September 11, 2026. The filing itself contains no financial results or operational metrics, so no performance data (positive or negative) is available for analysis.

14-09-2026

Hydro One Inc. filed a Form 6-K with the SEC on September 14, 2026, reporting a news release dated September 11, 2026. The filing is a routine foreign private issuer report under Rule 13a-16 or 15d-16, signed by General Counsel Cassidy McFarlane. No specific financial or operational details are provided in the filing itself, only the cover page and exhibit index referencing the news release.

• · The filing is for the month of September 2026.
• · Commission file number: 001-36115.
• · The company's address is 483 Bay Street, South Tower, 8th Floor, Toronto, Ontario M5G 2P5, Canada.
• · The company files annual reports under Form 40-F.

14-09-2026

Synchrony Financial filed an 8-K on September 14, 2026, furnishing monthly charge-off and delinquency statistics for the thirteen months ended August 31, 2026, under Regulation FD. The company intends to continue providing these statistics monthly, with quarter-end data released alongside quarterly earnings. The filing does not include any specific financial figures or period-over-period comparisons, only a commitment to ongoing disclosure.

• · The filing covers monthly charge-off and delinquency statistics for the thirteen months ended August 31, 2026.
• · The company will continue to furnish these statistics monthly, with quarter-end data released alongside quarterly earnings announcements.
• · The information is furnished under Item 7.01 and is not deemed filed for SEC liability purposes.

14-09-2026

Pacific Airport Group (GPAEF) filed a Form 6-K with the SEC on September 14, 2026, signed by CFO Saúl Villarreal García on September 11, 2026. The filing contains no substantive financial or operational data, only the signature page and basic identification.

14-09-2026

On September 8, 2026, TransparentBusiness, Inc. (Unicoin Inc.) announced the resignation of Deniece Ky, Principal Accounting Officer and Senior Financial Director, effective September 17, 2026, due to personal reasons. The company will pay $42,755.89 for accrued but unused PTO. No replacement has been announced, and no other financial or operational metrics were disclosed.

14-09-2026

Form 4 ownership filing; the structured EDGAR document could not be retrieved for automated parsing.

14-09-2026

CEO, President Heshmatpour Amir F bought 37,000 Common Stock at $3.67 (~$136K). Heshmatpour Amir F holds 3,133,000 shares after the transaction.

• · CEO, President Heshmatpour Amir F bought 37,000 Common Stock at $3.67 (~$136K)

14-09-2026

VinFast announced a leadership transition effective September 12, 2026, appointing Mr. Pham Nhat Quan Anh as CEO, succeeding Mr. Pham Nhat Vuong, who remains on the Board. Mr. Anh also becomes Chairman and CEO of VinFast Vietnam JSC. The change is intended to bring fresh perspectives and renewed momentum, with no financial metrics disclosed.

• · Mr. Pham Nhat Quan Anh has been with VinFast since February 2019, holding roles including Vice Chairman and Standing Deputy General Director of VinFast Vietnam JSC.
• · Prior to VinFast, Mr. Anh served as Deputy General Director and Deputy COO of Vinpearl JSC from 2017 to 2019.
• · Mr. Anh holds a Bachelor's degree in business management from Singapore Management University.
• · The Form 6-K is incorporated by reference into registration statements on Form S-8 (File No. 333-278251) and Form F-3 (File Nos. 333-275133 and 333-291445).

14-09-2026

Lipocine Inc. announced the initiation of its BLOOM Phase 3 study of LPCN 1154 for postpartum depression on September 14, 2026. The press release was furnished as Exhibit 99.1 to the 8-K filing. No financial results or period-over-period comparisons were provided in this filing.

• · The Phase 3 study is named BLOOM.
• · The study targets postpartum depression.
• · The press release was issued on September 14, 2026.

14-09-2026

Embrace Change Acquisition Corp. (EMCG) announced the termination of its merger agreement with Tianji Tire Global (Cayman) Limited, originally entered on January 26, 2025 and amended on October 16, 2025. Tianji delivered a termination notice on September 10, 2026, citing the failure to consummate the merger by the August 12, 2026 outside date. The termination was not due to any breach by EMCG, but the deal has been abandoned, leaving EMCG without a target business combination.

• · The Merger Agreement was originally signed on January 26, 2025 and amended on October 16, 2025.
• · The termination was effective as of September 10, 2026, per Section 11.1(d)(i) of the Merger Agreement.
• · The outside date for the merger was August 12, 2026.
• · The termination right was not available to a party if the failure to close was due to that party's breach; the filing does not indicate any breach by EMCG.